ISSN 1612-3352

Editors in Chief

Prof. Dr. Claus F. Claussen, Neurootological Research Institute of the Research Society for Smell, Taste, Hearing and Equilibrium Disorders at Bad Kissingen (4-G-F). Bad Kissingen, Germany.
Dr. med. Julia M. Bergmann,
Dr. med. Guillermo O. Bertora,
Otoneuroophthalmological Neurophysiology,
Buenos Aires, Argentina.

Production Managers

Dr. med. Julia M. Bergmann,
Dr. med. Guillermo O. Bertora,
Otoneuroophthalmological Neurophysiology,
Buenos Aires, Argentina.


Associated Editors


The editors welcome authors to submit articles for publications in the ASN.

Read the Information for Authors.


Kurhausstraße 12
D-97688 Bad Kissingen
Germany
Telefon +49-971-6 4832
Fax +49- 971- 6 8637
Email asn@neurootology.org

 

Sodium enoxaparin and venovenous hemofiltration for treatment of sudden sensorineural hearing loss and tinnitus.

Abstract

The pathogenesis of sudden sensorineural hearing loss (SNHL) and tinnitus are still not well understood. Prompted by such observations, we implemented a protocol using sodium enoxaparin associated with a venovenous hemofiltration for treatment of sudden hearing loss and tinnitus.
The venovenous hemofiltration selectively eliminates fibrinogen, low-density lipoprotein, cholesterol, triglycerides, lipoprotein and complement from the blood plasma by means of extracorporal circulation. The reduction of these macromolecules immediately improves the hemorheological situation and leads to a significant decrease of plasma viscosity and red cell transmission time.
Patients, who had suffered from SNHL and tinnitus, have been analysed. Hemofiltration was performed at the first and last day of the protocol while, to begin since the second day of the protocol, sodium enoxaparin was administered subcutaneously at a dose of 4000 I.U. once a day for 10 days.
Every day all patients underwent the following instrumental examinations: liminar tonal audiometry; otoacoustic emission; otoacoustic products of distortion. Blood tests where performed at the beginning, after the fist day and at the end of the treatment.
After the first hemofiltration, all the patients with complete auditive recovery have been discharged without receiving the treatment with sodium enoxaparin.
Specifically excluded were patients with abnormal known coagulation.

Login

Registration

If you are not already registered, please register here for free.

If you are registered but have forgotten your password (or you never had one), click here to recover your password.

Proceedings of

Authors

Archives

2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |

(bi)gital»